Rustin M H, Grimes S M, Kovacs I B, Cooke E D, Bowcock S A, Sowemimo-Coker S O, Turner P, Kirby J D
Eur J Clin Pharmacol. 1984;27(1):61-5.
Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.
招募了10名中重度雷诺综合征患者，进行为期四周的随机双盲交叉研究，以比较新型血栓素合成酶抑制剂UK-38,485 50毫克与安慰剂的疗效。就所使用的剂量而言，两个治疗期在缺血性发作的次数、严重程度和持续时间、手部平均温度、前臂和手指血流量以及红细胞流变学方面均无显著差异。
